Investigating a Vaccine Against COVID-19 (COV002) [COVID-19] [UPH]
Research type
Research Study
Full title
A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19
IRAS ID
281904
Contact name
Andrew J Pollard
Contact email
Sponsor organisation
CTRG
Eudract number
2020-001228-32
ISRCTN Number
ISRCTN90906759
Clinicaltrials.gov Identifier
CPMS 45551, ; ,
Duration of Study in the UK
1 years, 8 months, 31 days
Research summary
There are no currently licensed vaccines or specific treatments for COVID-19. This study will enable us to assess how well people of all ages can be protected from COVID-19 with this new vaccine called ChAdOx1 nCoV-19. It will also give us valuable information on safety aspects of the vaccine and its ability to generate good immune responses against COVID-19. We will enrol small numbers of older adults (56-70 years, then 70+ years) before expanding to large numbers of adults across all ages (18+ years). After this we will also assess the vaccine in a small group of children (5-12 years). In total we will enrol up to 5260 volunteers. There will be between 9 and 14 visits over 12 months with a blood test at each visit. Participants will receive one or two doses of the new COVID-19 vaccine or a licensed vaccine which has been given routinely to teenagers in the UK since 2015 to protect against meningitis and sepsis. Some participants may be asked to complete an electronic diary for 7 days after each vaccine and update the diary if they have any illness for a month after vaccination.
REC name
South Central - Berkshire Research Ethics Committee
REC reference
20/SC/0179
Date of REC Opinion
8 Apr 2020
REC opinion
Favourable Opinion